The Trump administration recently nixed a rule proposed by President Joe Biden that would have made it easier for 7.4 million Americans to afford antiobesity medications called GLP-1s. This was a mistake. These drugs, like Ozempic and Wegovy, can be a game changer. I know firsthand.

In July, I was prescribed a drug called Mounjaro. As a stroke survivor, I was interested in studies showing it could significantly reduce the risk of major cardiac events. Mounjaro is used to treat Type 2 diabetes, and a version recently received Food and Drug Administration approval for weight loss.

Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health. Aches, pains and stiffness have vanished. Physically, I feel a decade younger, clearer-headed, and more optimistic than I’ve been in years. As far as a side effects, I’ve also lost around 20 pounds.

And it’s not just me — millions of Americans have experienced similar life-changing benefits, regardless of why they started on these medications.

These drugs lower blood sugar, cholesterol, heart rate and heart inflammation. Some recent studies suggest they might even help curb alcohol addiction and support cognitive function, potentially slowing or preventing conditions like Parkinson’s and Alzheimer’s.

Before I go further, I want to be 100 percent clear: I’m not being compensated for talking about my treatment in any way, whatsoever. Zero. I’m just a guy who has benefited from these medications and wants to make sure that anyone else who could benefit from them can access them, too.